Human Organoids Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Human Organoids Market size was estimated at USD 990 million in 2023 and is projected to reach USD 2,300.38 million in 2030 at a CAGR of 12.80 % during the forecast period 2024-2030.

The human organoids market refers to the growing field of 3D cellular models that replicate the structure and function of human organs at a miniature scale. These organoids are derived from stem cells and are used in drug discovery, disease modelling, and regenerative medicine, offering more accurate alternatives to traditional 2D cell cultures. They enable researchers to better understand human biology, disease mechanisms, and responses to treatments, thus accelerating the development of new therapeutics and personalized medicine approaches.

The scope of the human organoids market has expanded significantly in recent years, driven by advancements in stem cell research, tissue engineering, and biotechnology. Key areas of application include drug testing, where organoids are used to evaluate the efficacy and safety of new drugs, and regenerative medicine, which focuses on using organoids to repair or replace damaged tissues. The market also has a growing presence in disease modelling, particularly for neurological, cardiovascular, and gastrointestinal diseases, as organoids provide a more relevant and realistic representation of human pathology.

Several factors are driving the growth of the human organoids market. The increasing demand for personalized medicine and more accurate preclinical models is pushing pharmaceutical companies to adopt organoid technologies. Additionally, the rising prevalence of chronic diseases, such as cancer, diabetes, and neurodegenerative disorders, has spurred investment in advanced research methods like organoid-based models. Regulatory pressure to improve drug development processes and reduce reliance on animal testing further enhances the appeal of organoids as a viable alternative.

The market is also influenced by trends such as the ongoing development of more sophisticated and complex organoid systems, including multi-organ models that replicate the interactions between different tissues. Advancements in artificial intelligence and machine learning are being integrated with organoid research, allowing for faster and more accurate predictions of drug responses and disease outcomes. Furthermore, collaborations between biotech companies, research institutions, and academic organizations are fuelling innovation and pushing the boundaries of organoid applications in therapeutic development.

Delvens Industry Expert's Standpoint

Experts in the Human Organoids Market highlight several key trends driving growth and innovation. The human organoids market is a rapidly growing sector focused on the development of 3D cellular models that mimic human organs, offering more accurate alternatives to traditional 2D cultures. These organoids are used in drug discovery, disease modelling, and regenerative medicine, providing insights into human biology, disease mechanisms, and treatment responses. The market is driven by the increasing demand for personalized medicine, the need for better preclinical models, and advancements in stem cell research and biotechnology. Trends such as the development of multi-organ models and integration with AI technologies are further accelerating growth, with significant investments aimed at improving therapeutic development and reducing reliance on animal testing.

Market Portfolio

Key Findings

• The human organoids market can be categorized based on product into liver, kidney, heart, pancreas, colorectal, lung, and other products. The liver models hold the largest market share, as the liver plays a critical role in metabolism, drug testing, toxicity studies, and disease modeling. Liver organoids closely replicate the complexity and function of actual liver tissue, making them significant in pharmacology and toxicology research. With the rising prevalence of liver diseases such as hepatitis and fatty liver disease, innovative models are increasingly needed, positioning the liver segment as a key area of growth and investment in the organoids market.

• The ready-to-use products segment leads the human organoids market in terms of type. This segment holds the largest market share due to the ease and efficiency with which researchers and companies can utilize ready-to-use organoids. Their convenience accelerates research timelines and reduces experimentation costs, which is particularly appealing to pharmaceutical companies and academic institutions. Ready-to-use organoids are also preferred for applications that require reliable results and enhanced reproducibility. As the demand for streamlined processes rises, the ready-to-use organoids segment continues to dominate the market.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such a rising chronic disease prevalence, increasing demand for personalized medicine, advancements in stem cell research, better drug development and testing, the need for accurate disease models, reduced animal testing reliance, 3D cell culture advancements, regenerative medicine expansion, and increased R&D investments. have triggered the Human Organoids Market in the region.

Regional Analysis

North America to Dominate the Market

• North America held the largest share of the global organoids market. This can be attributed to the rising number of patients with various diseases, increased investment in research and development, the commercialization of organoid models, and advancements in stem cell research.
• The organoids market in Europe is expected to grow significantly during the forecast period. The development of cerebral organoids for neurological diseases, along with the increasing prevalence of infectious and other diseases, is anticipated to drive market growth in the region. Additionally, ongoing investments in research and development focused on cancer, liver diseases, gastrointestinal diseases for organ regeneration, and stem cell research are expected to further boost the organoids market in Europe

Competitive Landscape

• Thermo Fisher Scientific Inc.
• Corning Incorporated
• Merck KGaA
• BioIVT
• HUB Organoids BV
• Bico
• Becytes Biotechnologies
• InSphero
• GBA Group
• Kirkstall Ltd.
• MIMETAS BV
• Neuromics
• Primacyt Cell Culture Technology GmbH
• STEMCELL Technologies
• Other Players:
• AcroBiosystems
• BioPredic International
• CN Bio Innovations Ltd.
• Cyprio
• Emulate, Inc.
• KeraFast, Inc.
• Pandorum Technologies Pvt. Ltd.
• Cyfuse Biomedical KK
• NeyroblastGX LLC
• 3DNamics Inc.
• Definigen Limited

Recent Developments

• In August 2024, BioIVT (US) acquired ZenBio (US), a leading provider of advanced cell products and services. The two companies will collaborate to offer an expanded portfolio of skin-based expertise, primary cell and exosome isolation, and blood products for the pharmaceutical and cosmetics industries.

• n June 2024, Corning Incorporated (US) entered into a partnership with the National Institute for Bioprocessing Research and Training (NIBRT) (Ireland), a center for biopharmaceutical manufacturing research and training. As part of this collaboration, Corning will install one of its Ascent Fixed Bed Bioreactor (FBR) Systems at NIBRT’s Advanced Therapies building in Dublin, Ireland. This move strengthens Corning’s presence in the European life sciences market, particularly in the growing Irish market.

• In July 2024, Merck KGaA (Germany) began commercial production at its first GMP-compliant cell culture media (CCM) manufacturing line.

• In May 2024, InSphero (Switzerland) formed an exclusive global partnership with Genome Biologics (Germany) to commercialize Genome Biologics’ innovative 3D Cardiac Organoid Platform. This platform, which leads in cardiac disease research, offers accurate, scalable, and disease-specific organoid models crucial for the development of new therapeutics.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Human Organoids Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope